Juliet BA - Kymera Therapeutics Head Research
| KYMR Stock | USD 33.04 0.83 2.45% |
Executive
Juliet BA is Head Research of Kymera Therapeutics
| Phone | 857 285 5300 |
| Web | https://www.kymeratx.com |
Kymera Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.2065) % which means that it has lost $0.2065 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3638) %, meaning that it created substantial loss on money invested by shareholders. Kymera Therapeutics' management efficiency ratios could be used to measure how well Kymera Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Minji MBA | Mineralys Therapeutics, Common | N/A | |
| Isabel Chiu | C4 Therapeutics | N/A | |
| Xiaolin Wang | Revolution Medicines | 54 | |
| Mark Mossler | C4 Therapeutics | 51 | |
| Kevin Johnston | Cullinan Oncology LLC | N/A | |
| Laurent MBA | Prelude Therapeutics | 59 | |
| Bryant JD | Prelude Therapeutics | 53 | |
| Jan Smith | Revolution Medicines | N/A | |
| Michael MD | Century Therapeutics | 53 | |
| Paige Mahaney | C4 Therapeutics | N/A | |
| Danielle Bradbury | Mineralys Therapeutics, Common | N/A | |
| Steven Vickers | Agios Pharm | N/A | |
| David MD | Mineralys Therapeutics, Common | 70 | |
| Morgan Conn | Century Therapeutics | 56 | |
| Sarah Foster | Mineralys Therapeutics, Common | N/A | |
| Roy Pollock | C4 Therapeutics | N/A | |
| Jessica Ibbitson | Mineralys Therapeutics, Common | N/A | |
| William MD | Prelude Therapeutics | N/A | |
| Kelli MS | Shattuck Labs | N/A | |
| WanJen MD | Prelude Therapeutics | 46 | |
| Mayra ReyesArmour | C4 Therapeutics | N/A | |
Management Performance
| Return On Equity | -0.36 | ||||
| Return On Asset | -0.21 |
Kymera Therapeutics Leadership Team
Elected by the shareholders, the Kymera Therapeutics' board of directors comprises two types of representatives: Kymera Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Kymera. The board's role is to monitor Kymera Therapeutics' management team and ensure that shareholders' interests are well served. Kymera Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Kymera Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jared MD, Chief Officer | ||
| DPhil DPHIL, CoFounder Chairman | ||
| JD Esq, Chief Secretary | ||
| Karen Weisbach, Head Culture | ||
| Juliet BA, Head Research | ||
| Melissa Brody, VP Devel | ||
| Elaine Caughey, Chief Officer | ||
| Bruce CFA, Chief Officer | ||
| Dr DPHIL, CoFounder Chairman | ||
| Kevin Dushney, VP Operations | ||
| Vijay Sabesan, VP Operations | ||
| Michael Todisco, VP Fin | ||
| Nello MD, President, CoFounder | ||
| Jeremy Chadwick, Chief Officer |
Kymera Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Kymera Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.36 | ||||
| Return On Asset | -0.21 | ||||
| Operating Margin | (10.92) % | ||||
| Current Valuation | 1.84 B | ||||
| Shares Outstanding | 64.94 M | ||||
| Shares Owned By Insiders | 2.49 % | ||||
| Shares Owned By Institutions | 97.51 % | ||||
| Number Of Shares Shorted | 7.34 M | ||||
| Price To Book | 2.68 X | ||||
| Price To Sales | 46.95 X |
Pair Trading with Kymera Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Kymera Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Kymera Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Kymera Stock
Moving against Kymera Stock
| 0.77 | VALN | Valneva SE ADR | PairCorr |
| 0.67 | DOMH | Dominari Holdings | PairCorr |
| 0.56 | MDCX | Medicus Pharma | PairCorr |
| 0.55 | MGTX | MeiraGTx Holdings PLC | PairCorr |
| 0.43 | MDGL | Madrigal Pharmaceuticals | PairCorr |
The ability to find closely correlated positions to Kymera Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Kymera Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Kymera Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Kymera Therapeutics to buy it.
The correlation of Kymera Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Kymera Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Kymera Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Kymera Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Kymera Stock Analysis
When running Kymera Therapeutics' price analysis, check to measure Kymera Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Kymera Therapeutics is operating at the current time. Most of Kymera Therapeutics' value examination focuses on studying past and present price action to predict the probability of Kymera Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Kymera Therapeutics' price. Additionally, you may evaluate how the addition of Kymera Therapeutics to your portfolios can decrease your overall portfolio volatility.